PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 27, 2025Journal of Medicinal Chemistry3 citations

Application of Weighted Interaction-Fingerprints for Rationalizing Neosubstrate Potency and Selectivity of Cereblon-Based Molecular Glues

View Full Paper
GLGuilian LuchiniBristol-Myers Squibb (Germany)SLShuang LiuTianjin University of Traditional Chinese MedicineHPHannah L. PowersBristol-Myers Squibb (Germany)

Key Points

  • Enhanced designs of CRBN-based molecular glues improve neosubstrate selectivity and efficacy.
  • Computational methods analyze ligand interactions in the neosubstrate ternary complex, revealing critical insights.
  • Optimizing ligand interactions is crucial to minimize off-target activity in potent CRBN-based therapies.
  • Ongoing trials are exploring diverse neosubstrates, including GSPT1 and CK1α, for proteasome-dependent degradation.

Abstract

Cullin-RING Ligase 4 Cereblon (CRL4CRBN) (CRBN) E3 ligase modulatory drugs (CELMoDsTM) make up a successful class of compounds targeting neosubstrates for proteasome-dependent degradation. Early immunomodulatory drugs (IMiDsTM) target Ikaros and Aiolos degradation. In addition, there are ongoing clinical trials targeting the degradation of biologically relevant proteins such as GSPT1, CK1α, and Helios with CRBN-based molecular glues. To date, most advanced preclinical and clinical CRBN-based molecular glues recruit their neosubstrates through canonical G-motifs, secondary protein features that are structurally similar but have significantly different amino acid sequence identities. Analogous to the development of kinase inhibitors, optimizing both neosubstrate recruitment and degradation selectivity is important to minimize potential off-target activity. Here, we describe a computational structure-based approach to analyze and predict putative ligand interactions important in the neosubstrate ternary complex. This approach provides valuable insights for enhanced designs toward the development of more selective and efficacious CRBN-based molecular glues.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Luchini et al. (2025) studied this question.

synapsesocial.com/papers/68d7be5eeebfec0fc52374fchttps://doi.org/10.1021/acs.jmedchem.5c01919
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix2019 · 7,645 citations
  2. 2Data processing and analysis with the autoPROC toolbox2011 · 2,163 citations
  3. 3Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.2020 · 4 citations
  4. 4Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM2022 · 11 citations
  5. 5The interplay between HPIP and casein kinase 1α promotes renal cell carcinoma growth and metastasis via activation of mTOR pathway2016 · 22 citations